Abstract |
Glutamate, an excitatory central nervous system neurotransmitter, is emerging as a potential alternative pharmacological treatment when compared to gamma-aminobutyric acid ( GABA)-, dopamine-, and serotonin-modulating treatments for neuropsychiatric conditions. The pathophysiology, animal models, and clinical trials of glutamate modulation are explored in disorders with underlying inhibitory deficits (cognitive, motor, behavioral) including obsessive-compulsive disorder, attention deficit hyperactivity disorder, Tourette syndrome, trichotillomania, excoriation disorder, and nail biting. Obsessive-compulsive disorder, attention deficit hyperactivity disorder, and grooming disorders ( trichotillomania and excoriation disorder) have emerging positive data, although only scarce controlled trials are available. The evidence is less supportive for the use of glutamate modulators in Tourette syndrome. Glutamate-modulating agents show promise in the treatment of disorders of inhibition.
|
Authors | Marco A Grados, Elizabeth B Atkins, Gabriela I Kovacikova, Erin McVicar |
Journal | Psychology research and behavior management
(Psychol Res Behav Manag)
Vol. 8
Pg. 115-31
( 2015)
ISSN: 1179-1578 [Print] New Zealand |
PMID | 25995654
(Publication Type: Journal Article, Review)
|